Synta Pharmaceuticals Corp.

Lexington, Mass. • 781-274-8200 • www.syntapharma.com

Exchange and Ticker: Nasdaq: SNTA

Filing Range: 6M shares @ $14.00 to $16.00

Offering Price: $10.00

Close on First Day: $9.09

Offering Size: $50M

Shares Outstanding: 33,817,434

Underwriters: Bear Stearns & Co. Inc./ Lehman Brothers

Co-managers: Lazard Capital Markets/ Montgomery & Co.

Company Counsel: Mintz Levin Cohn Ferris Glovsky & Popeo

Manager Counsel: Ropes & Gray

Auditor: KPMG LLP

Market Capitalization on 2/28/07: $288.46 M

Close price at current month end: $8.53

DESCRIPTION

Develops small-molecule drugs for cancer and chronic inflammatory diseases. The company is a biopharmaceutical business focused on discovering, developing, and commercializing products for extending the lives of patients with severe medical conditions. Synta has three drug candidates in preclinical or clinical development, and an additional five programs in late-stage research. Competitors include Johnson & Johnson, Amgen, Wyeth Pharmaceuticals, Abbott Laboratories, Elan Corp.

VENTURE BACKERS

Aperture Venture Partners; CxSynta LLC (managed by hedge fund Caxton Corp.); Galleon Group; SunAmerica Ventures

Sources: Thomson Financial and SEC filings.